Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis
| العنوان: | Efficacy and safety of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy for advanced EGFR-mutated non-small cell lung cancer: systematic review and meta-analysis |
|---|---|
| المؤلفون: | Lee, H.J., Jeong, G., Li, H., Kim, M., Kim, J., Park, S.J., Han, Y.J., Lee, K.H., Kronbichler, A., Hong, S.H., Ghayda, R.A., Luchini, C., Nottegar, A., Koyanagi, A., Smith, L., Jacob, L., Dragioti, E., Radua, J., Cargnin, S., Terrazzino, S., Thompson, T., Yon, D.K., Lee, S.W., Yang, J.M., Wasuwanich, P., Shin, J.L., Gamerith, G. |
| بيانات النشر: | Verduci Editore, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | RC0254, ErbB Receptors, Survival Rate, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Mutation, Humans, QD, Antineoplastic Agents, Protein Kinase Inhibitors, Progression-Free Survival, respiratory tract diseases |
| الوصف: | OBJECTIVE: It is controversial whether there is efficacy or safety benefit of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in advanced EGFR-mutated non-small cell lung cancer (NSCLC) compared to standard chemotherapy. We aim to assess the efficacy and safety of EGFR-TKIs compared to other chemotherapeutics in EGFR-mutated NSCLC.\ud \ud MATERIALS AND METHODS: Up to April 27th, 2020, PubMed, Embase, Medline, Scopus, Cochrane library, and ClinicalTrials.gov were searched for articles or trials meeting the inclusion criteria. After filtering, 230 eligible studies were initially identified. Data extraction followed PRISMA and included outcomes were progression-free survival (PFS), overall survival (OS), and severe adverse events (SAEs). Direct and indirect meta-analyses were generated in the context of log-linear mixed-effects models, with fixed effects for each relative comparison and random effects for each study.\ud \ud RESULTS: The results showed that EGFR-TKI therapy had improved PFS with a hazard ratio (HR) of 0.40 (95% CI: 0.36-0.44, p |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2284-0729 1128-3602 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c28ef085067790fba186e02ec094bb69Test https://arro.anglia.ac.uk/id/eprint/706477/5/Lee_et_al_2021.pdfTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.pmid.dedup....c28ef085067790fba186e02ec094bb69 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 22840729 11283602 |
|---|